Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 11 years
- Director since
- 2023
11 years of board service in total across 4 boards, counting each seat separately. Longest: Halozyme Therapeutics Inc., 3 years.
Halozyme Therapeutics Inc.
Director
ACADIA Pharmaceuticals Inc.
Director
Madrigal Pharmaceuticals Inc.
Director
Cytokinetics Incorporated
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Madrigal Pharmaceuticals Inc. June 16, 202696.6%
-
Madrigal Pharmaceuticals Inc. June 15, 202360.0%
-
ACADIA Pharmaceuticals Inc. June 1, 202379.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 15, 2026 | Cytokinetics Incorporated | Grant or award | +151 | $82.62 | $12,476 |
| Jun 17, 2026 | Madrigal Pharmaceuticals Inc. | Grant or award | +454 | — | — |
| May 29, 2026 | ACADIA Pharmaceuticals Inc. | Option exercise | +8,107 | — | — |
| May 27, 2026 | Cytokinetics Incorporated | Grant or award | +2,851 | — | — |
| Apr 15, 2026 | Cytokinetics Incorporated | Grant or award | +191 | $65.37 | $12,486 |
| Jan 15, 2026 | Cytokinetics Incorporated | Grant or award | +197 | $63.44 | $12,498 |
| Nov 10, 2025 | ACADIA Pharmaceuticals Inc. | Open-market sale | −30,000 | $22.37 | $671,100 |
| Jun 20, 2025 | Madrigal Pharmaceuticals Inc. | Grant or award | +715 | — | — |
| May 29, 2025 | ACADIA Pharmaceuticals Inc. | Option exercise | +9,387 | — | — |
| Feb 27, 2025 | Madrigal Pharmaceuticals Inc. | Option exercise | +9,470 | $65.06 | $616,118 |
| Feb 27, 2025 | Madrigal Pharmaceuticals Inc. | Option exercise | +6,000 | $111.06 | $666,360 |
| Feb 27, 2025 | Madrigal Pharmaceuticals Inc. | Open-market sale | −398 | $346.90 | $138,066 |
| Feb 27, 2025 | Madrigal Pharmaceuticals Inc. | Open-market sale | −14,302 | $347.39 | $4,968,372 |
| Feb 27, 2025 | Madrigal Pharmaceuticals Inc. | Open-market sale | −770 | $348.94 | $268,684 |
| Jun 25, 2024 | Madrigal Pharmaceuticals Inc. | Grant or award | +714 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.